Current Report Filing (8-k)
June 02 2020 - 7:02AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
June 1, 2020
TREVENA, INC.
(Exact name of registrant as specified in
its charter)
Delaware
(State or other jurisdiction of incorporation)
001-36193
|
|
26-1469215
|
|
|
|
(Commission
File No.)
|
|
(IRS Employer
Identification No.)
|
955 Chesterbrook Boulevard, Suite 110
Chesterbrook, PA 19087
(Address of principal executive offices
and zip code)
Registrant’s telephone number, including
area code: (610) 354-8840
Not applicable
(Former name or former address, if changed
since last report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section
12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, $0.001 par value
|
TRVN
|
The Nasdaq Stock Market LLC
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company
¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
|
Item 7.01
|
Regulation
FD Disclosure
|
On June 2, 2020, Trevena, Inc. (the “Company”)
updated its website to include an updated corporate presentation deck. A copy of the updated corporate deck is attached
hereto as Exhibit 99.2.
The information set forth on this Item 7.01 and furnished hereto
as Exhibit 99.2 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended
(the “Exchange Act”), and is not incorporated by reference into any of the Company’s filings under the Securities
Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth
by specific reference in any such filing.
Cautionary Note on Forward Looking Statements
Any
statements in Item 7.01 of this Current Report on Form 8-K, including within Exhibit 99.2 hereto about future expectations,
plans and prospects for the Company, including statements about the Company’s strategy, future operations, clinical development
and trials of its therapeutic candidates, plans for potential future product candidates and other statements containing the words
“anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,”
“plan,” “predict,” “project,” “suggest,” “target,” “potential,”
“will,” “would,” “could,” “should,” “continue,” and similar expressions,
constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results
may differ materially from those indicated by such forward-looking statements as a result of various important factors, including:
the status, timing, costs, results and interpretation of the Company’s clinical trials or any future trials of any of the
Company’s investigational drug candidates; the uncertainties inherent in conducting clinical trials; expectations for regulatory
interactions, submissions and approvals, including the Company’s assessment of the discussions with FDA, the timing of FDA’s
decision on the oliceridine NDA; available funding ; uncertainties related to the Company’s intellectual property; uncertainties
related to the ongoing COVID-19 pandemic, other matters that could affect the availability or commercial potential of the Company’s
therapeutic candidates; and other factors discussed in the Risk Factors set forth in the Company’s Annual Report on Form
10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission (SEC) and in other filings the Company
makes with the SEC from time to time. In addition, the forward-looking statements included in this Current Report on Form 8-K,
including Exhibit 99.2 hereto, represent the Company’s views only as of the date hereof. The Company anticipates that subsequent
events and developments may cause the Company’s views to change. However, while the Company may elect to update these forward-looking
statements at some point in the future, it specifically disclaims any obligation to do so, except as may be required by law.
On June 2, 2020, the Company issued a press release
announcing that it has entered into a collaboration with Imperial College London to evaluate the potential of TRV027, a novel
AT1 receptor selective agonist, to treat acute lung injury contributing to acute respiratory distress syndrome
(ARDS) in COVID-19 patients. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on
Form 8-K and is incorporated herein by reference.
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
TREVENA, INC.
|
|
|
|
|
Date:
June 2, 2020
|
By:
|
/s/ Barry Shin
|
|
|
Barry Shin
Senior Vice President & Chief Financial Officer
|
Trevena (NASDAQ:TRVN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Trevena (NASDAQ:TRVN)
Historical Stock Chart
From Apr 2023 to Apr 2024